German clinical diagnostics leader partners with US genomics innovator to advance cancer testing
Cancer diagnostics in Germany is set to enter a new phase as Labor Dr. Wisplinghoff collaborates with US-based Genomic Testing Cooperative to implement advanced molecular testing capabilities, with RNA analysis at the forefront of this precision medicine initiative.
Partnership expands comprehensive cancer diagnostics in Germany
One of Germany’s largest medical laboratories, Labor Dr. Wisplinghoff, has entered into a strategic partnership with Genomic Testing Cooperative (GTC), a California-based molecular testing company specialising in RNA innovation. Announced on 18 March 2025, this collaboration will introduce GTC’s comprehensive suite of Next Generation Sequencing (NGS) DNA/RNA tests to the German healthcare market.
The partnership enables Labor Dr. Wisplinghoff to expand its analytical capabilities in pathology and haematology by adopting GTC’s portfolio of tissue and liquid biopsy testing for both solid tumours and haematologic neoplasms. This implementation will provide German physicians with deeper molecular insights to guide more precise diagnosis and therapy monitoring for cancer patients.
RNA analysis transforms clinical utility
A central focus of this collaboration is the comprehensive RNA analysis technology, which represents a significant advancement in clinical utility for cancer diagnostics. The expanded molecular analyses will provide physicians with more robust data for developing optimised precision treatment plans, potentially improving therapy outcomes for patients across Germany.
Professor Hilmar Wisplinghoff, Managing Partner at Labor Dr. Wisplinghoff, commented: “We are excited to partner with GTC and to bring cutting-edge advances in genomics and precision medicine into the German healthcare space. We believe that together we can be at the forefront of developing and deploying products and services that offer ‘step change’ patient outcomes in the treatment of cancers in Germany.”
Cooperative model enables global research participation
By joining GTC’s cooperative (Co-Op) group, Labor Dr. Wisplinghoff gains access to proprietary capabilities and datasets, along with opportunities to participate in coordinated global research and development initiatives and clinical trial programmes. This membership is expected to accelerate the laboratory’s contribution to precision medicine advancement within the German healthcare landscape.
Dr. Maher Albitar, Founder, CEO and Chief Medical Officer at GTC, added: “We are very thrilled to partner with Labor Dr. Wisplinghoff in adapting and bringing to Germany our proven and comprehensive portfolio of tissue and liquid biopsy tests for Hematologic Neoplasms and Solid Tumours. Both our companies are focused on innovation and serving patients, and through our partnership we aim to be instrumental in driving the democratization of genomic testing in Germany and making it available and affordable to every patient with cancer.”
Strengthening Europe’s precision oncology infrastructure
This collaboration represents a significant addition to Western Europe’s precision medicine capabilities. Labor Dr. Wisplinghoff, founded in 1977, has established itself as one of the largest independent private medical laboratories in Western Europe, providing comprehensive testing services to various medical entities throughout Germany and beyond.
